United Therapeutics Corporation announced today that the U.S. FDA will require additional time to complete its review of the New Drug Application for Tyvaso (inhaled treprostinil). In a notice received today, the FDA extended the Prescription Drug User Fee Act date from April 30, 2009, to July 30, 2009.
The details can be read here.
No comments:
Post a Comment